du Bois Score for IPF Mortality
Predicts 1-year mortality in IPF from a single clinical visit using age, hospitalisation history, %predicted FVC, and 24-week FVC change. du Bois risk score ranges 0–100.
Score interpretation
du Bois score 0–7: estimated 1-year mortality < 2 %.
→ Lower short-term risk — continue specialist ILD follow-up and FVC monitoring.
du Bois score 8–15: estimated 1-year mortality 2–5 %.
→ Lower short-term risk — continue specialist ILD follow-up and FVC monitoring.
du Bois score 16–21: estimated 1-year mortality 5–10 %.
→ Intermediate risk — review antifibrotic therapy and monitoring with the ILD team.
du Bois score 22–29: estimated 1-year mortality 10–20 %.
→ Intermediate risk — review antifibrotic therapy and monitoring with the ILD team.
du Bois score 30–33: estimated 1-year mortality 20–30 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 34–37: estimated 1-year mortality 30–40 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 38–40: estimated 1-year mortality 40–50 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 41–43: estimated 1-year mortality 50–60 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 44–46: estimated 1-year mortality 60–70 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 47–49: estimated 1-year mortality 70–80 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
du Bois score 50–61: estimated 1-year mortality > 80 %.
→ High short-term mortality risk — discuss treatment escalation, transplant assessment and palliative care needs with the ILD team; advance care planning.
Interpretation bands for the du Bois Score. Apply clinical judgement and local guidance.
References
- du Bois RM, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–466.
Related
Curated clinical cross-links plus same-class fallbacks.
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.